CTOs on the Move


 
Xellia Pharmaceuticals is a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections. Our anti-infective treatments are generics that combat serious bacterial and antibiotic resistant infections as well as certain fungal diseases.
  • Number of Employees: 1K-5K
  • Annual Revenue: $10-50 Million
  • www.xellia.com
  • 8841 Wadford Drive
    Raleigh, NC USA 27616
  • Phone: 919.327.5500

Executives

Name Title Contact Details

Similar Companies

Neponset Controls Inc

Neponset Controls Inc is a Foxboro, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Care Solace

Care Solace is a social purpose organization founded with the mission to implement systemic solutions for sustainable, equitable access to mental health care. Providing a human and technology approach, Care Solace navigates the mental health care system and finds the right help for everyone in every community regardless of coverage, including private insurance, Medicaid, and sliding scale options for those without insurance. We match individuals to more than 350,0000 verified providers, perform a Warm Handoff®, and follow-up on care. Care Solace expands on existing social programs and employer EAPs and bridges the gaps for needs that exceed the scope of those services. Founded in 2017, Care Solace has proudly completed over 6.5 million support interactions across 600 organizations nationwide.

AppianRx

We are a healthcare solutions company that provides comprehensive and customized manufacturer patient support services and specialty pharmacy solutions. AppianRx leverages its unique and proprietary technology platform to deliver personalized services faster, smarter and more efficiently for patients, providers and manufacturer partners.

ALDA Pharmaceuticals

ALDA Pharmaceuticals Corp. is a Richmond, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cognito Therapeutics

Cognito Therapeutics is a pioneer in non-invasive neuromodulation to treat neurodegenerative diseases and improve human cognitive performance. The company has completed multiple clinical studies demonstrating its investigational therapeutic has the potential to safely slow or stop cognitive decline and loss of brain volume in Alzheimer`s disease. Cognito has received FDA Breakthrough Device Designation for the treatment of Alzheimer`s disease and expects to start pivotal studies in 2022. The company`s technology was based on pioneering optogenetics research by scientific co-founders Professors Li-Huei Tsai and Ed Boyden at MIT.